Objectives: This paper reviews current and emerging therapies for multiple myeloma (MM).
Methods: Narrative review.
Results: MM is a complex, heterogenous condition, and in recent years there has been an expansion in the number and range of treatments. Several new treatment approaches, including enhanced monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen-T-cell therapy are under development.
Conclusions: The emergence of new treatments that aim to tackle MM-associated immune dysfunction has led to improvements in overall survival.
Keywords: ADC; BiTE; CAR-T; celmod; immunotherapy; melflufen; monoclonal antibody; multiple myeloma; selinexor; venetoclax.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.